Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 377, Issue 4-6, 2008, Pages 637-645

  Krzyzanski, Wojciech ^a   Wyska, Elzbieta ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Internalization; Pharmacokinetic model; Receptor binding; Target mediated drug disposition

Indexed keywords

ERYTHROPOIETIN RECEPTOR; RECOMBINANT ERYTHROPOIETIN;

COMPUTER SIMULATION; CONFERENCE PAPER; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; INTERNALIZATION; MALE; OXYGEN SATURATION; TURNOVER TIME;

CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; ERYTHROPOIETIN, RECOMBINANT; HUMANS; MALE; MODELS, BIOLOGICAL; PROTEIN BINDING; RECEPTORS, ERYTHROPOIETIN; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 45849125816     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-007-0225-z     Document Type: Conference Paper

References (32)

1. Altin JG, White FAJ, Easton CJ (2001) Synthesis of the chelator lipid nitrilotriacetic acid ditetradecylamine (NTA-DTDA) and its use with the IAsys biosensor to study receptor-ligand interactions on model membranes. Biochem Biophys Acta 1513:131-148
2. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T (1991) Erythropoietin receptor characteristics on primary human erythroid cells. Blood 77:2583-2590
3. Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA (2001) Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 298:820-824
4. Cheung K, Goon BL, Guilfoyle MC, Wacholtz MC (1998) Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 64:412-423
5. D'Argenio DZ, Schumitzky A (1997) ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic System Analysis Software. Biomedical Simulations Resource, Los Angeles
6. Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med 228:1-14
7. Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH (1990) Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 47:557-564
8. Glaspy J, Henry D, Patel R, Tchekmedyian S, Applebaum S, Berdeaux D, Lloyd R, Berg R, Austin M, Rossi G, the Darbepoetin Alfa 20010162 Study Group (2005) Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomized clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Caner 41:1140-1149
9. Gogu SR, Malter JS, Agrawal KC (1992) Zidovudine induced blockade of the expression and function of the erythropoietin receptor. Biochem Pharmacol 44:1009-1012
10. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, Abraham PA (1991) Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50:702-712
11. Jelkmann W (1992) Erythropoietin: structure, control of production, and function. Physiol Rev 72:449-489
12. Kenakin TP (1987) Pharmacologic analysis of drug-receptor interaction. Raven Press, New York
13. Kinoshita H, Ohishi N, Kato M, Tokura S, Okazaki A (1992) Pharmacokinetics and distribution of recombinant human erythropoietin in rats. Arzneim-Forsch/Drug Res 42:174-178
14. Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF (1995) Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80:729-38
15. Krzyzanski W, Jusko WJ, Wacholtz MC, Minton N, Cheung WK (2005) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci 26:295-306
16. Lacombe C, Mayeux P (1998) Biology of erythropoietin. Haematologica 83:724-732
17. Levy G (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56:248-52
18. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532
19. Mager DE, Wyska E, Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510-18
20. Pasqualetti P, Casale R (1996) Circadian rhythm of serum erythropoietin in healthy subjects. Riv Eur Sci Med Farmacol 18:91-93
21. Pasqualetti P, Collacciani A, Casale R (2000) Circadian rhythm of serum erythropoietin in myelodysplastic syndroms. Riv Eur Sci Med Farmacol 4:111-115
22. Philo JS, Aoki KH, Arakawa T, Owers Narhi L, Wen J (1996) Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry 35:1681-1691
23. Piroso E, Erslev AJ, Caro J (1989) Inappropriate increase in erythropoietin titers during chemotherapy. Am J Hematol 32:248-254
24. Ramakrishnan R, Cheung WK, Farrell F, Joffee L, Jusko WJ (2003) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J Pharmacol Exp Ther 306:324-331
25. Ramakrishnan R, Cheung WK, Wacholtz MC, Winton N, Jusko WJ (2004) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 44:991-1002
26. Rowland M, Tozer TN (1995) Clinical pharmacokinetics. Concepts and applications. Williams & Wilkins, Philadelphia
27. Sawyer ST, Krantz SB, Goldwasser E (1987) Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem 262:5554-5562
28. Sugiyama Y, Hanano M (1989) Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body. Pharm Res 6:192-202
29. Spivak JL, Cotes PM (1991) The pharmacokinetics and metabolism of erythropoietin. In: Erslev AJ, Adamson JW, Eschbach JW, Winearls CG (eds) Erythropoietin, molecular, cellular, and clinical biology. The John Hopkins University Press, Baltimore, MD
30. Spivak JL, Barnes DC, Fuchs E, Quinn TC (1989) Serum immunoreactive erythropoietin in HIV-infected patients. J Am Med Assoc 210:3104-3107
31. Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, Widness JA (2003) A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep. J Pharmacol Exp Ther 306:532-537
32. Walrafen P, Verdier F, Kadri Z, Chretien S, Lacombe C, Mayeux P (2005) Both proteosome and lysosome degrade the activated erythropoietin receptor. Blood 105:600-608